Endomedix, Inc. news

Endomedix announced today that it received a patent of 30 issued claims for its PLEXimine™ Polysaccharide Technology platform for a new class of biomaterials. The patent, “Methods and Compositions for Achieving Hemostasis and Stable Clot Formation”, also covers design features and mechanisms of action for its first product based on the technology. This technology platform produces structured

Endomedix, Inc. announced today that it has entered into a Cooperative Research and Development Agreement or CRADA with the US. Army Institute of Surgical Research (USAISR) and the U.S. Army Medical Materiel Development Activity (USAMMDA). The CRADA will address a specific topic, “Ocular Projectile Battlefield Trauma Project”, an unsolved emergency medical treatment problem for warfighters injured during battle.

“This project is a result of a meeting and subsequent d

Endomedix, Inc. announced today the first of a series of publications of its research and patented technology for a new family of biomaterials based on natural polysaccharides.  Appearing in the Journal of Applied Polymer Science, the article, “Reproducible, biocompatible medical materials from biologically derived polysaccharides: Processing and Characterization”, addresses the methods and tasks to develop a tunable technology that can be designed

Endomedix, Inc., today announced that it will present its patented revolutionary technology to control bleeding in battlefield injuries at the upcoming Military Health System and Research Symposium (MHSRS) annual meeting.  Loss of blood still remains the most common cause of potentially preventable deaths in battlefield casualties, two-thirds of such deaths result from truncal hemorrhage that cannot be controlled with tourniquets. The poster will feature the biopolymer technology’s

Endomedix, Inc., a developer of unique biosurgical products based on natural biopolymer systems, today announced it will provide the first public presentation of its work at a scientific meeting. The 2019 Annual Meeting is scheduled for April 3-6 in Seattle, Washington. The presentation will provide data and descriptions of the performance of its patented hydrogel biomaterial in a series of hemostatic applications in progressively more challenging bleeding wounds. This data will include the i